Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Generation Expands In AstraZeneca's Vacated Campus

This article was originally published in Scrip

Executive Summary

When AstraZeneca plc decided three years ago to relocate its R&D headquarters from its Alderley Park campus in the Northwest of England to be nearer the biotech action around Cambridge, a research park built to accommodate thousands of scientists suddenly faced the prospect of becoming a ghost town. However, for Dr Neil Murray, CEO of local firm Redx Pharma, the site represents a great opportunity.

You may also be interested in...



Redx Rises Out Of Administration With R&D Refocus

After a tough summer, the UK firm has exited insolvency with new management and programs in cancer and fibrosis, having decided to shut down its anti-infectives business.

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

Scrip Asks… What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement

Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC064962

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel